Literature DB >> 25553892

Characterization of TRIF selectivity in the AGP class of lipid A mimetics: role of secondary lipid chains.

Juhienah K Khalaf1, William S Bowen2, Hélène G Bazin1, Kendal T Ryter1, Mark T Livesay1, Jon R Ward1, Jay T Evans1, David A Johnson3.   

Abstract

TLR4 agonists that favor n class="Gene">TRIF-dependent signaling and the induction of type 1 interferons may have potential as vaccine adjuvants with reduced toxicity. CRX-547 (4), a member of the aminoalkyl glucosaminide 4-phosphate (AGP) class of lipid A mimetics possessing three (R)-3-decanoyloxytetradecanoyl groups and d-relative configuration in the aglycon, selectively reduces MyD88-dependent signaling resulting in TRIF-selective signaling, whereas the corresponding secondary ether lipid 6a containing (R)-3-decyloxytetradecanoyl groups does not. In order to determine which secondary acyl groups are important for the reduction in MyD88-dependent signaling activity of 4, the six possible ester/ether hybrid derivatives of 4 and 6a were synthesized and evaluated for their ability to induce NF-κB in a HEK293 cell reporter assay. An (R)-3-decanoyloxytetradecanoyl group on the 3-position of the d-glucosamine unit was found to be indispensable for maintaining low NF-κB activity irrespective of the substitutions (decyl or decanoyl) on the other two secondary positions. These results suggest that the carbonyl group of the 3-secondary lipid chain may impede homodimerization and/or conformational changes in the TLR4-MD2 complex necessary for MyD88 binding and pro-inflammatory cytokine induction.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AGP; Glycolipids; Lipid A mimetic; NF-κB activity; TLR4 agonist; TRIF selectivity; Vaccine adjuvant

Mesh:

Substances:

Year:  2014        PMID: 25553892      PMCID: PMC4330088          DOI: 10.1016/j.bmcl.2014.12.024

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  44 in total

Review 1.  Use of defined TLR ligands as adjuvants within human vaccines.

Authors:  Malcolm S Duthie; Hillarie Plessner Windish; Christopher B Fox; Steven G Reed
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  SDZ MRL 953, a novel immunostimulatory monosaccharidic lipid A analog with an improved therapeutic window in experimental sepsis.

Authors:  C Lam; E Schütze; J Hildebrandt; H Aschauer; E Liehl; I Macher; P Stütz
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Divalent cations affect chain mobility and aggregate structure of lipopolysaccharide from Salmonella minnesota reflected in a decrease of its biological activity.

Authors:  Patrick Garidel; Michael Rappolt; Andra B Schromm; Jörg Howe; Karl Lohner; Jörg Andrä; Michel H J Koch; Klaus Brandenburg
Journal:  Biochim Biophys Acta       Date:  2005-09-15

4.  Synthesis of endotoxic principle of bacterial lipopolysaccharide and its recognition by the innate immune systems of hosts.

Authors:  Shoichi Kusumoto; Koichi Fukase
Journal:  Chem Rec       Date:  2006       Impact factor: 6.771

5.  Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa.

Authors:  Umeharu Ohto; Koichi Fukase; Kensuke Miyake; Yoshinori Satow
Journal:  Science       Date:  2007-06-15       Impact factor: 47.728

6.  Two neisseria meningitidis strains with different ability to stimulate toll-like receptor 4 through the MyD88-independent pathway.

Authors:  T H Mogensen; S R Paludan; M Kilian; L Østergaard
Journal:  Scand J Immunol       Date:  2006-12       Impact factor: 3.487

7.  Structure-activity relationship of synthetic toll-like receptor 4 agonists.

Authors:  Axel G Stöver; Jean Da Silva Correia; Jay T Evans; Christopher W Cluff; Mark W Elliott; Eric W Jeffery; David A Johnson; Michael J Lacy; Jory R Baldridge; Peter Probst; Richard J Ulevitch; David H Persing; Robert M Hershberg
Journal:  J Biol Chem       Date:  2003-10-21       Impact factor: 5.157

8.  The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

Authors:  Verónica Mata-Haro; Caglar Cekic; Michael Martin; Paula M Chilton; Carolyn R Casella; Thomas C Mitchell
Journal:  Science       Date:  2007-06-15       Impact factor: 47.728

9.  Agonistic and antagonistic properties of a Rhizobium sin-1 lipid A modified by an ether-linked lipid.

Authors:  Mahalakshmi Vasan; Margreet A Wolfert; Geert-Jan Boons
Journal:  Org Biomol Chem       Date:  2007-05-29       Impact factor: 3.876

10.  Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection.

Authors:  Ganesh A Kolumam; Sunil Thomas; Lucas J Thompson; Jonathan Sprent; Kaja Murali-Krishna
Journal:  J Exp Med       Date:  2005-08-29       Impact factor: 14.307

View more
  1 in total

Review 1.  Immunobiology and application of toll-like receptor 4 agonists to augment host resistance to infection.

Authors:  Antonio Hernandez; Naeem K Patil; Cody L Stothers; Liming Luan; Margaret A McBride; Allison M Owen; Katherine R Burelbach; David L Williams; Edward R Sherwood; Julia K Bohannon
Journal:  Pharmacol Res       Date:  2019-11-02       Impact factor: 7.658

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.